Kieren Mather MD FRCPC
Diabetes, Lipid Metabolism
Associate Vice President Early Diabetes Research
Join to View Full Profile
975 W Walnut StIb 424Indianapolis, IN 46202
Phone+1 317-944-8660
Dr. Mather is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Calgary Faculty of MedicineClass of 1992
Certifications & Licensure
IN State Medical License 1999 - 2027
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification P2 Sentinel, Cerner Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification Powerchart (Image Results), Cerner Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification FirstNet, Cerner Healthe and IQHealth, Cerner Corporation, 2013-2017
Clinical Trials
- Treating the Endothelium to Restore Insulin Sensitivity Start of enrollment: 2005 Jun 01
- Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls Start of enrollment: 2009 Mar 01
- Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake Start of enrollment: 2012 Jan 01
Publications & Presentations
PubMed
- Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.Tim Heise, Eric Zijlstra, Andrea Mari, William C Roell, Kieren J Mather
Diabetes, Obesity & Metabolism. 2026-06-02 - 1 citationsEloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.Shobha Bhattachar, Lai San Tham, Beth Tidemann-Miller, Hilda Ibriga, Hongchang Qu
Diabetes, Obesity & Metabolism. 2026-04-01 - 2 citationsLong-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose st...William Roell, Jorge Alsina-Fernandez, Hongchang Qu, Tamer Coskun, Charles Benson
Molecular Metabolism. 2026-01-01
Journal Articles
- Genetic Ancestry Markers and Difference in A1c Between African-American and White in the Diabetes Prevention ProgramSteven Kahn, William C Knowler, Kieren J Mather, Jose C Florez, The Journal of Clinical Endocrinology and Metabolism
- Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 DiabetesKieren J Mather, Mark A Green, The Journal of Clinical Endocrinology and Metabolism
Press Mentions
Type 2 Diabetes Medications Don’t Prevent the Disease in People with Prediabetes, Study SuggestsJune 11th, 2019
Complication Rates Ramp up in Kids with T2DJune 9th, 2019
Two RISE Clinical Trials in Youth and Adults with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes Reveal Surprising Differences in Beta-Cell (Β-cell) Function During and After TreatmentJune 9th, 2019
Grant Support
- Preservation Of Beta Cell Function In Prediabetes/Early Type 2 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2011
- Preservation Of Beta Cell Function In Prediabetes Early Type 2 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2011
- Modulation Of Human Myocardial Metabolism By GLP-1National Heart, Lung, And Blood Institute2010–2011
- Repaglinide As A Viable Alternative To Pre-Meal Insulin In Cystic Fibrosis RENational Center For Research Resources2007–2008
- Myocardial Substrate Selection And Switching In Lean And Obese HumansNational Center For Research Resources2007–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
